Antiglaucoma carbonic anhydrase inhibitors: a patent review

Bibliography

• Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal disease and glaucoma. Nature Rev Drug Discov 2012;11:541-59
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Patents 2012;22:79-88
   PubMed Web of Science ®Google Scholar
• Quigley HA. Glaucoma. Lancet 2011;377:1367-77
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:151-6
   Google Scholar
• Mincione F, Menabuoni L, Supuran CT. Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase – its inhibitors and activators. CRC Press, Boca Raton (FL); 2004. p. 243-54
   Google Scholar
• Mincione F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors as ophthalmologic drugs. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken; 2009. p. 139-54
   Google Scholar
• Supuran C, Benedini F, Biondi S, et al. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
   Google Scholar
• Chong W, Kwan M, Nukui S. 1-[4-(Sulfonyl)-phenyl]-5-benzyl-1H, 1,2,4-triazole derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension. WO075152; 2008
   Google Scholar
• Sinha S, Bhat SS, Heidelbaugh TM, et al. Heterocyclic substituted fused carbocycles useful in the treatment of conditions such as glaucoma. WO023758; 2009
   Google Scholar
• Ruckmick S, Cain R, Abreo MJ, et al. Novel compounds and their use related to compositions for treating glaucoma and/or ocular hypertension. WO050615; 2007
   Google Scholar
• McIntire GL, Davio SR, Harms AE, et al. Complexes comprising alpha-2-adrenergic receptor agonists and methods of providing neuroprotection or treating or inhibiting progression of glaucoma. US0183946; 2011
   Google Scholar
• Old DW. Pyrrolidinones for the treatment of glaucoma and ocular hypertension. WO005176; 2007
   Google Scholar
• Burk RM. Novel sulfonamides. WO024611; 2007
   Google Scholar
• Woodward DF, Chen J. EP2 receptor agonists for treating glaucoma. WO027468; 2007
   Google Scholar
• Prasanna G, Bosworth CF, La Fontaine JA. EP2 agonists. WO015517; 2008
   Google Scholar
• Holoboski M, Burk RM, Posner MF. Therapeutic compounds. WO073752; 2008
   Google Scholar
• Old DW. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure. WO144623; 2008
   Google Scholar
• Dinh DT, Old DW, Burk RM. Therapeutic beta-lactams. WO091764; 2009
   Google Scholar
• Maxey KM, Stanton ML. Internal 1,15-lactones of fluprostenol and related prostaglandin F2A analogs and their use in the treatment of glaucoma and intraocular hypertension. US0146821; 2008
   Google Scholar
• Woodward DF, Burk RM. Novel prostamides for the treatment of glaucoma and related diseases. US0112058; 2007
   Google Scholar
• Bakhit PG, Graham R, Olejnik O. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia. US0244051; 2007
   Google Scholar
• Johnson BA, Old DW, Donde Y, et al. Therapeutic compounds. US0186885; 2009
   Google Scholar
• Reunamaki T, Pellinen P, Oksala O, et al. Method and composition for treating ocular hypertension and glaucoma. US0152264; 2011
   Google Scholar
• Hellberg MR, Namil A, Feng Z, et al. Phenylethylamine analogs and their use for treating glaucoma. WO038372; 2007
   Google Scholar
• Dantanarayana AP, May JA. Substituted furo[2,3-G]indazoles for the treatment of glaucoma. US0012291; 2009
   Google Scholar
• Abdulrazik M. Novel compounds for the treatment of glaucoma or ocular hypertension. US0305710, 2011
   Google Scholar
• Borriello M, Pucci S, Stasi LP, et al. Cyclic amide derivatives as EP4 receptor antagonists. WO004291; 2013
   Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2000;10:575-600
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008;7:168-81
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 2010;16:3233-45
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
   PubMed Web of Science ®Google Scholar
• Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review (2008 – 2011). Expert Opin Ther Pat 2012;22:903-15
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Patents 2006;16:1627-64
   Web of Science ®Google Scholar
• Aggarwal M, Boone CD, Kondeti B, et al. Structural annotation of human carbonic anhydrases. J Enzyme Inhib Med Chem 2013;28:267-77
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68
   PubMed Web of Science ®Google Scholar
• Hewitson KS, Supuran CT. Carbonic anhydrase inhibitors for treating dandruff and related disorders. WO061185; 2010
   Google Scholar
• Supuran CT, Parkkila S. Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. WO139678; 2010
   Google Scholar
• Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. WO098610; 2011
   Google Scholar
• Supuran C, Dedhar S, McDonald P, et al. Novel sulfonamide compounds for inhibition of metastatic tumor growth. WO021963; 2012
   Google Scholar
• Supuran C, Dedhar S, Carta F, et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO070024; 2012
   Google Scholar
• Masereel B, Frederick R, Supuran CT. Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders. WO175654; 2012
   Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72
   PubMed Web of Science ®Google Scholar
• Bootorabi F, Jänis J, Hytönen VP, et al. Acetaldehyde-derived modifications on cytosolic human carbonic anhydrases. J Enzyme Inhib Med Chem 2011;26:862-70
   PubMed Web of Science ®Google Scholar
• Liu F, Martin-Mingot A, Lecornué F, et al. Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry. J Enzyme Inhib Med Chem 2012;27:886-91
   PubMed Web of Science ®Google Scholar
• Cavdar H, Ekinci D, Talaz O, et al. α-Carbonic anhydrases are sulfatases with cyclic diol monosulfate esters. J Enzyme Inhib Med Chem 2012;27:148-54
   PubMed Web of Science ®Google Scholar
• Kazancıoğlu EA, Güney M, Sentürk M, et al. Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity. J Enzyme Inhib Med Chem 2012;27:880-5
   PubMed Web of Science ®Google Scholar
• Alp C, Ozsoy S, Alp NA, et al. Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI. J Enzyme Inhib Med Chem 2012;27:818-24
   PubMed Web of Science ®Google Scholar
• Ekinci D, Kurbanoglu NI, Salamcı E, et al. Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds. J Enzyme Inhib Med Chem 2012;27:845-8
   PubMed Web of Science ®Google Scholar
• Ekinci D, Al-Rashida M, Abbas G, et al. Chromone containing sulfonamides as potent carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:744-7
   PubMed Web of Science ®Google Scholar
• Singh S, Supuran CT. QSARs on human carbonic anhydrase VA and VB inhibitors of some new not yet synthesized, substituted aromatic/heterocyclic sulphonamides as anti-obesity agent. J Enzyme Inhib Med Chem 2012;27:666-72
   PubMed Web of Science ®Google Scholar
• Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization and inhibition studies of an alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem 2012;55:10742-8
   PubMed Web of Science ®Google Scholar
• Capasso C, De Luca V, Carginale V, et al. Biochemical properties of a novel and highly thermostable bacterial alpha-carbonic anhydrase from Sulfurihydrogenibium yellowstonense YO3AOP1. J Enzyme Inhib Med Chem 2012;27:892-7
   PubMed Web of Science ®Google Scholar
• De Luca V, Vullo D, Scozzafava A, et al. Anion inhibition studies of an alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1. Bioorg Med Chem Lett 2012;22:5630-4
   PubMed Web of Science ®Google Scholar
• Vullo D, De Luca V, Scozzafava A, et al. The first activation study of a bacterial carbonic anhydrase (CA). The thermostable alpha-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines. Bioorg Med Chem Lett 2012;22:6324-7
   PubMed Web of Science ®Google Scholar
• Vullo D, De Luca V, Scozzafava A, et al. Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense. Bioorg Med Chem Lett 2012;22:7142-5
   PubMed Web of Science ®Google Scholar
• Friedenwald JS. The formation of the intraocular fluid. Am J Ophthalmol 1949;32:9-27
   PubMed Web of Science ®Google Scholar
• Kinsey VE. Comparative chemistry of aqueous humor in posterior and anterior chambers of rabbit eye. Arch Ophthalmol 1953;50:401-17
   PubMed Web of Science ®Google Scholar
• Kinsey VE, Barany E. The rate flow of aqueous humor. II. Derivation of rate of flow and its physiologic significance. Am J Ophthalmol 1949;32:189-202
   PubMed Web of Science ®Google Scholar
• Wistrand PJ. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand 1951;24:144-8
   Google Scholar
• Becker B. The mechanism of the fall in intraocular pressure by the carbonic anhydrase inhibitor Diamox. Am J Ophthalmol 1955;39:177-83
   PubMed Web of Science ®Google Scholar
• Kinsey VE, Reddy DVN. Turnover of total carbon dioxide in aqueous humors and the effect thereon of acetazolamide. Arch Ophthalmol 1959;62:78-83
   PubMed Web of Science ®Google Scholar
• Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Top Med Chem 2007;7:849-54
   PubMed Web of Science ®Google Scholar
• Maren TH. Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967;47:595-781
   PubMed Web of Science ®Google Scholar
• Liao SY, Ivanov S, Ivanova A, et al. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J Med Genet 2003;40:257-61
   PubMed Web of Science ®Google Scholar
• Miller WH, Dessert AM, Roblin RO. Jr. Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J Am Chem Soc 1950;72:4893-6
   Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Development of sulfonamide carbonic anhydrase inhibitors (CAIs). In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase – its inhibitors and activators. CRC Press, Boca Raton (FL); 2004. p. 67-147
   Google Scholar
• Maren TH, Jankowska L, Sanyal G, et al. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res 1983;36:457-80
   PubMed Web of Science ®Google Scholar
• Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Progr Ret Eye Res 2000;19:87-112
   PubMed Web of Science ®Google Scholar
• Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:45-9
   PubMed Web of Science ®Google Scholar
• Silver LH. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide dose-response study group. Surv Ophthalmol 2000;44(Suppl 2):147-53
   Google Scholar
• Aalto-Korte K. Contact allergy to dorzolamide eye drops. Contact Dermat 1998;39:206
   PubMed Web of Science ®Google Scholar
• Carlsen J, Durcan J, Swartz M, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999;117:1087-8
   PubMed Web of Science ®Google Scholar
• Thoe Schwartzenberg GW, Trop GE. Anorexia, depression and dementia induced by dorzolamide eye drops (Trusopt). Can J Ophthalmol 1999;34:93-4
   PubMed Web of Science ®Google Scholar
• Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;127:403-6
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999;42:2641-50
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long lasting-intraocular pressure lowering properties via the topical route. J Med Chem 1999;42:3690-700
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. J Med Chem 2000;43:4542-51
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long lasting, topical intraocular pressure lowering properties. J Med Chem 2002;45:1466-76
   PubMed Web of Science ®Google Scholar
• Chiroli V, Batugo MR, Biondi S, et al. Synthesis of novel nitric oxide (NO) – releasing esters of timolol. Bioorg Med Chem Lett 2009;19:2785-8
   PubMed Web of Science ®Google Scholar
• Steele RM, Batugo MR, Benedini F, et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 2009;19:6565-70
   PubMed Web of Science ®Google Scholar
• Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216-21
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138-47
   PubMed Web of Science ®Google Scholar
• Benedini F, Biondi S, Ongini E. Carbonic anhydrase inhibitors derivatives. WO075155; 2008
   Google Scholar
• Patterson B, Rui E. Thieno[3,2-e][1,2]thiazine derivative as inhibitor of carbonic anhydrase. WO120099; 2008
   Google Scholar
• Huang Q, Rui E. Inhibitors of carbonic anhydrase. WO007814; 2009
   Google Scholar
• Long DD, Frieman B, Hegde SS, et al. A Multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 2013;23:939-43
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165-80
   PubMed Web of Science ®Google Scholar
• Nair SK, Rui EY. Tricyclic inhibitors of carbonic anhydrase. WO075148; 2008
   Google Scholar
• Schoen U, Waldeck H, Reinecker U, et al. Novel sulfamate compounds for medical use. WO050252; 2009
   Google Scholar
• Antel J, Waldeck H, Schoen U, et al. N-Sulfamoyl-N’-benzopyranpiperidine compounds and uses thereof. US0117823; 2007
   Google Scholar
• Antel J, Waldeck H, Schoen U, et al. N-Sulfamoyl-N’-benzopyranpiperidines as inhibitors of carbonic anhydrases. WO054580; 2007
   Google Scholar
• Matulis D, Dudutiene V, Matuliene J, et al. Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof. WO016288; 2008
   Google Scholar
• Baranauskiene L, Hilvo M, Matuliene J, et al. Inhibition and binding studies of carbonic anhydrase isozymes I, II and IX with benzimidazo[1,2-c] [1,2,3] thiadiazole-7-sulphonamides. J Enzyme Inhib Med Chem 2010;25:863-70
   PubMed Web of Science ®Google Scholar
• Gant TG. Sulfonamide inhibitors of carbonic anhydrase II. US0125067; 2010
   Google Scholar
• Rao T, Zhang C. Sulfonamide inhibitors of carbonic anhydrase. US0317655; 2010
   Google Scholar
• Chang JN, Hughes PM, Devries GW. Carbonic anhydrase inhibitor sustained release intraocular drug delivery system. US0034448; 2011
   Google Scholar
• Inoue J, Shah T. Ophthalmic composition. WO140194; 2011
   Google Scholar
• Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511-22
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-62
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335-44
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271-7
   PubMed Web of Science ®Google Scholar
• Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun (Cambridge) 2012;48:1868-70
   PubMed Web of Science ®Google Scholar
• Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55:1721-30
   PubMed Web of Science ®Google Scholar
• Monti SM, Maresca A, Viparelli F, et al. Dithiocarbamates strongly inhibit the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorg Med Chem Lett 2012;22:859-62
   PubMed Web of Science ®Google Scholar
• Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;28:407-11
   PubMed Web of Science ®Google Scholar
• Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-Ray crystal studies of the carbonic anhydrase II – trithiocarbonate adduct – an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20:474-8
   PubMed Web of Science ®Google Scholar
• Molnar F, Siguero R, Sato Y, et al. 1alpha,25(OH)2-3-Epi-Vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor. PLoS One 2011;6:e18124
   PubMed Web of Science ®Google Scholar
• Kutuzova G, Gabelt BAT, Kiland JA, et al. 1alpha,25-Dihydroxyvitamin D3 and its analog, 2-methylene-19-nor (20S)-1α,25-dihydroxyvitamin D3 (2MD), suppress intraocular pressure in non-human primates. Arch Biochem Biophys 2012;518:53-60
   PubMed Web of Science ®Google Scholar